Literature DB >> 3493441

Efficacy of astatine-211-labeled monoclonal antibody in treatment of murine T-cell lymphoma.

A Harrison, L Royle.   

Abstract

The short-lived isotope 211At (half-life, 7.2 hr), an alpha particle-emitting halogen, has been attached to a monoclonal antibody (anti-thy 1.1, IgG1, OX7) and used in mice in the treatment of a thy 1.1 T-cell lymphoma (A120). Forty-eight hours after receiving an iv injection of 10(3) or 10(5) A120 cells, mice were treated with phosphate-buffered saline, 211At-, antibody alone, or 211At conjugated to OX7. Treatment with the 211At-labeled OX7 conjugate increased the median survival time of mice and probably "cured" (survival at 200 days) 6 of the 15 mice given 10(5) cells and 21 of the 27 mice given 10(3) cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493441

Source DB:  PubMed          Journal:  NCI Monogr        ISSN: 0893-2751


  6 in total

Review 1.  Cancer radioimmunotherapy with alpha-emitting nuclides.

Authors:  Olivier Couturier; Stéphane Supiot; Marie Degraef-Mougin; Alain Faivre-Chauvet; Thomas Carlier; Jean-François Chatal; François Davodeau; Michel Cherel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05       Impact factor: 9.236

2.  Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

Authors:  M R Zalutsky; P K Garg; H S Friedman; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

4.  Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.

Authors:  R H Larsen; O S Bruland
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

5.  Analysis of the therapeutic gain in the treatment of human osteosarcoma microcolonies in vitro with 211At-labelled monoclonal antibody.

Authors:  R H Larsen; O S Bruland; P Hoff; J Alstad; E K Rofstad
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

6.  Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells.

Authors:  E Aurlien; R H Larsen; G Kvalheim; O S Bruland
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.